Compare Neurocrine Biosciences Inc (NBIX) vs Twilio Inc (TWLO) Price & Performance

Neurocrine Biosciences IncTrade

Twilio IncTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Twilio Inc — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $16.46B), while Twilio Inc trades at $255.1 (market cap $39.31B). The key difference: Twilio Inc is far larger — about 2.4× Neurocrine Biosciences Inc's market cap, and Twilio Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

	NBIX	TWLO
Market Cap	$16.46B	$39.31B
Sector	Health	Technology
52-Week High	$185.50	$255.95
52-Week Low	$123.10	$95.23
Enterprise Value	$16.48B	$37.72B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Twilio Inc

Twilio (TWLO) trades at $250.06, up 3.64% with strong technical momentum and bullish moving average signals. The stock has delivered three consecutive earnings beats, with Q2 2026 EPS of $1.47 beating expectations by 11%. Revenue growth accelerated to 22% year-over-year in Q2, prompting management to raise full-year guidance to 18-18.5% growth. The company achieved record free cash flow generation with margins improving significantly.

Twilio presents compelling growth prospects with accelerating revenue and robust cash flow generation. However, elevated valuation multiples (P/E 35.35, EV/EBITDA 75.54) and overbought technical indicators suggest near-term consolidation risk. Analyst consensus remains strongly bullish with 77% buy ratings and $266.31 price target, representing 6.5% upside from current levels.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 5 hours agoBullish View details →

TWLO

Twilio stock jumps 80% YTD on strong Q2 results and raised FY26 growth guidance.Seeking Alpha · 1 day agoBullish Twilio beats Q2 estimates, shares soar 113% since February on strong growth and cash flow.Seeking Alpha · 2 days agoBullish Software stocks swing as AI fears hit valuations; Atlassian and Twilio rally after earnings.CNBC · 4 days agoNeutral View details →

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

About Twilio Inc

Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.